Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Immune & inflammatory · 2025

Anzupgo (delgocitinib)

The FDA approved Anzupgo (delgocitinib) on July 23, 2025 to treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response.
Brand name
Anzupgo
Generic name
delgocitinib
FDA approval date
July 23, 2025
Approved use (FDA wording)
To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
Company
Leo Pharma As
Application
NDA219155
Dosage form / route
CREAM · TOPICAL
Drug class (EPC)
Janus Kinase Inhibitor [EPC]
Boxed warning on label
Not listed
Category on this site
Immune & inflammatory

Indications and usage, from the FDA label

ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Limitations of Use Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ANZUPGO is a Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ( 1 ) Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.